Pictet Asset Management Holding SA Acquires 286,325 Shares of TG Therapeutics, Inc. $TGTX

Pictet Asset Management Holding SA raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,747,373 shares of the biopharmaceutical company’s stock after buying an additional 286,325 shares during the quarter. Pictet Asset Management Holding SA owned 1.09% of TG Therapeutics worth $58,048,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of TGTX. Maryland State Retirement & Pension System increased its stake in shares of TG Therapeutics by 2.0% in the 4th quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 393 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in TG Therapeutics by 1.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock worth $1,135,000 after acquiring an additional 441 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 16.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 454 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in TG Therapeutics by 1.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,062 shares of the biopharmaceutical company’s stock worth $926,000 after purchasing an additional 500 shares during the period. Finally, Pingora Partners LLC grew its holdings in TG Therapeutics by 31.2% in the fourth quarter. Pingora Partners LLC now owns 2,100 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 500 shares during the period. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Down 0.2%

TG Therapeutics stock opened at $55.72 on Tuesday. The firm has a market capitalization of $8.53 billion, a price-to-earnings ratio of 19.48 and a beta of 1.68. The firm’s fifty day moving average price is $42.62 and its two-hundred day moving average price is $34.78. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $57.38. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The business had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. During the same period in the previous year, the firm earned $0.03 earnings per share. The company’s revenue was up 69.5% on a year-over-year basis. On average, equities research analysts predict that TG Therapeutics, Inc. will post 1.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of TG Therapeutics in a report on Wednesday, May 27th. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $83.00 target price on shares of TG Therapeutics in a research report on Monday, June 22nd. Finally, Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $58.60.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.